Aperçu des produits pour anti-MAP2K7 (MAP2K7) Anticorps

Full name:
anti-Mitogen-Activated Protein Kinase Kinase 7 Anticorps (MAP2K7)
Chez www.anticorps-enligne.fr sont 144 Mitogen-Activated Protein Kinase Kinase 7 (MAP2K7) Anticorps de 22 de différents fournisseurs disponibles. De plus, nous expédions MAP2K7 Kits (14) et MAP2K7 Protéines (13) et beaucoup plus de produits pour cette protéine. Un total de 182 MAP2K7 produits sont actuellement listés.
2, 5930412N11Rik, JNKK, JNKK 2, Jnkk2, MAP2K7, map2k7-A, MAPKK7, MAPKK 7, Mek7, MEK 7, MKK7, Prkmk7, SAPKK-4, SAPKK4, sek2, si:ch211-254d18.2

Réactivités les plus populaires pour anti-MAP2K7 (MAP2K7) Anticorps

Sélectionnez vos espèces et l'application

anti-Rat (Rattus) MAP2K7 Anticorps:

anti-Human MAP2K7 Anticorps:

anti-Mouse (Murine) MAP2K7 Anticorps:

Tous anti-MAP2K7 Anticorps disponible

Vous arrivez à notre recherche pré-filtrée.

anti-MAP2K7 Anticorps mieux référencés

  1. Human Monoclonal MAP2K7 Primary Antibody pour ICC, FACS - ABIN969271 : Yoshizawa, Hammaker, Sweeney, Boyle, Firestein: Synoviocyte innate immune responses: I. Differential regulation of interferon responses and the JNK pathway by MAPK kinases. dans Journal of immunology (Baltimore, Md. : 1950) 2008 (PubMed)
    Show all 2 references for 969271

  2. Cow (Bovine) Polyclonal MAP2K7 Primary Antibody pour WB - ABIN2783609 : Tornatore, Marasco, Dathan, Vitale, Benedetti, Papa, Franzoso, Ruvo, Monti: Gadd45 beta forms a homodimeric complex that binds tightly to MKK7. dans Journal of molecular biology 2008 (PubMed)

  3. Human Polyclonal MAP2K7 Primary Antibody pour ELISA, WB - ABIN1450653 : Mungall, Palmer, Sims, Edwards, Ashurst, Wilming, Jones, Horton, Hunt, Scott, Gilbert, Clamp, Bethel, Milne, Ainscough, Almeida, Ambrose, Andrews, Ashwell, Babbage, Bagguley, Bailey, Banerjee, Barker et al.: The DNA sequence and analysis of human chromosome 6. ... dans Nature 2003 (PubMed)

Plus d’anticorps contre MAP2K7 partenaires d’interaction

Human Mitogen-Activated Protein Kinase Kinase 7 (MAP2K7) interaction partners

  1. In an Eastern Chinese population, carriers of MAP2K7 rs3679T variant genotypes had an increased risk of NSCLC.

  2. Therefore, EGF (Montrer EGF Anticorps) is suggested to induce E-cadherin (Montrer CDH1 Anticorps) down-regulation at the transcriptional level through the MEK (Montrer MAP2K1 Anticorps)/ERK (Montrer EPHB2 Anticorps) pathway, which might result in, at least in part, the induction of cellular morphological changes and cell migration in LoVo cells.

  3. combined pan-RAF and MEK inhibition can overcome intrinsic and acquired resistance to single-agent RAF/MEK inhibition, supporting dual pan-RAF and MEK inhibition as a novel therapeutic strategy for BRAF- and KRAS-mutant cancers

  4. our study suggested that black rice anthocyanins extract suppress metastasis in breast cancer cells by targeting the RAS/RAF (Montrer RAF1 Anticorps)/MAPK (Montrer MAPK1 Anticorps) pathway

  5. Crystal structures of the wild type and C218S mutant of MAP2K7 were determined. Cys218 plays a crucial role in configuring an auto-inhibition form of MAP2K7.

  6. We found that the MKK7 p.Glu116Lys rare polymorphism was significantly associated with lung cancer risk, progression and prognosis

  7. we explored the effects of selumetinib in combination with gefitinib in a panel of TNBC cells, in order to evaluate whether the simultaneous blockade of the EGFR (Montrer EGFR Anticorps) and the RAS/MEK (Montrer MAP2K1 Anticorps)/ERK (Montrer EPHB2 Anticorps) pathway might increase the antitumor activity of selumetinib in TNBC.

  8. a widespread role for the JNK (Montrer MAPK8 Anticorps)-CELF2 (Montrer CELF2 Anticorps) axis in controlling splicing during T-cell activation, including a specific role in propagating JNK (Montrer MAPK8 Anticorps) signaling.

  9. This review will focus on the science and clinical findings related to targeted therapies that inhibit BRAF (Montrer BRAF Anticorps) or MEK (Montrer MAP2K1 Anticorps) as well as the immunotherapies that block the CTLA-4 (Montrer CTLA4 Anticorps) or PD-1 (Montrer PDCD1 Anticorps) pathways

  10. BCR-ABL (Montrer ABL1 Anticorps) promotes PTEN (Montrer PTEN Anticorps) downregulation through a MEK (Montrer MAP2K1 Anticorps) dependent pathway.

Mouse (Murine) Mitogen-Activated Protein Kinase Kinase 7 (MAP2K7) interaction partners

  1. The loss of mkk4 (Montrer MAP2K4 Anticorps) and mkk7 locks damaged exocrine cells in a permanently de-differentiated state.

  2. Arrestin-3 (Montrer ARRB2 Anticorps) directly interacts with MKK7 and promotes JNK3alpha2 phosphorylation by both MKK4 (Montrer MAP2K4 Anticorps) and MKK7 in vitro as well as in intact cells.

  3. MKK7 is specifically phosphorylated in the neurite shaft which triggers Map1b (Montrer MAP1B Anticorps) phosphorylation to regulate microtubule bundling leading to neurite elongation.

  4. Data indicate that mitogen activated protein kinase kinase 7 (MKK7) plays a critical regulatory role in the c-Jun N-terminal kinase pathway in a murine model of rheumatoid arthritis.

  5. a novel function for the stress kinase MKK7 as a regulator of the circadian clock in mammalian cells at steady state.

  6. Distinct signaling properties of mitogen-activated protein kinase kinases 4 (MKK4) and 7 (MKK7) in embryonic stem cell (ESC) differentiation.

  7. MKK4 (Montrer MAP2K4 Anticorps)/7 and JNK1 (Montrer MAPK8 Anticorps)/2 played regulatory role in cytoskeleton reorganization during vaccinia virus infection.

  8. This study demonistrated that Stress-activated protein kinase (Montrer CDK7 Anticorps) MKK7 regulates axon elongation in the developing cerebral cortex.

  9. The results reveal an essential role of MKK7 in cardiomyocytes for protecting the heart from hypertrophic insults thereby preventing the transition to heart failure.

  10. The role of NF-kappaB (Montrer NFKB1 Anticorps) and c-jun N-terminal kinase (JNK) activation in RANKL (Montrer TNFSF11 Anticorps)-induced osteoclast differentiation was investigated using an adenovirus vector carrying the dominant negative 1kappaB kinase 2 gene or dominant negative MKK7 gene.

MAP2K7 profil antigène

Antigen Summary

The protein encoded by this gene is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase specifically activates MAPK8/JNK1 and MAPK9/JNK2, and this kinase itself is phosphorylated and activated by MAP kinase kinase kinases including MAP3K1/MEKK1, MAP3K2/MEKK2,MAP3K3/MEKK5, and MAP4K2/GCK. This kinase is involved in the signal transduction mediating the cell responses to proinflammatory cytokines, and environmental stresses. Multiple alternatively spliced transcript variants encoding distinct isoforms have been found, but only one transcript variant has been supported and defined.

Alternative names and synonyms associated with MAP2K7

  • mitogen-activated protein kinase kinase 7 (MAP2K7) anticorps
  • mitogen activated protein kinase kinase 7 (Map2k7) anticorps
  • mitogen-activated protein kinase kinase 7 (Map2k7) anticorps
  • mitogen-activated protein kinase kinase 7 (map2k7) anticorps
  • 2 anticorps
  • 5930412N11Rik anticorps
  • JNKK anticorps
  • JNKK 2 anticorps
  • Jnkk2 anticorps
  • MAP2K7 anticorps
  • map2k7-A anticorps
  • MAPKK7 anticorps
  • MAPKK 7 anticorps
  • Mek7 anticorps
  • MEK 7 anticorps
  • MKK7 anticorps
  • Prkmk7 anticorps
  • SAPKK-4 anticorps
  • SAPKK4 anticorps
  • sek2 anticorps
  • si:ch211-254d18.2 anticorps

Protein level used designations for MAP2K7

mitogen-activated protein kinase kinase 7 , JNK kinase 2 , JNK-activating kinase 2 , JNKK 2 , MAP kinase kinase 7 , MAPK/ERK kinase 7 , MAPKK 7 , MEK 7 , c-Jun N-terminal kinase kinase 2 , dual specificity mitogen-activated protein kinase kinase 7 , SAPK kinase 4 , stress-activated protein kinase kinase 4 , mitogen activated protein kinase kinase 7 , protein kinase, mitogen activated, kinase 7

787278 Bos taurus
100302082 Ovis aries
363855 Rattus norvegicus
5609 Homo sapiens
485004 Canis lupus familiaris
26400 Mus musculus
560913 Danio rerio
394391 Xenopus laevis
Fournisseurs de qualité sélectionnés pour anti-MAP2K7 (MAP2K7) Anticorps
Avez-vous cherché autre chose?